Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 162 citing articles:

2016 European Guidelines on cardiovascular disease prevention in clinical practice
Massimo Piepoli, Arno W. Hoes, Stefan Agewall, et al.
European Heart Journal (2016) Vol. 37, Iss. 29, pp. 2315-2381
Open Access | Times Cited: 5960
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Massimo Piepoli, Arno W. Hoes, Stefan Agewall, et al.
European Journal of Preventive Cardiology (2016) Vol. 23, Iss. 11, pp. NP1-NP96
Open Access | Times Cited: 1148
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
Kevin Fitzgerald, Suellen White, Anna Borodovsky, et al.
New England Journal of Medicine (2016) Vol. 376, Iss. 1, pp. 41-51
Open Access | Times Cited: 682
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Massimo Piepoli, Arno W. Hoes, Stefan Agewall, et al.
Atherosclerosis (2016) Vol. 252, pp. 207-274
Open Access | Times Cited: 451
Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab
Paul M. Ridker, Jean‐Claude Tardif, Pierre Amarenco, et al.
New England Journal of Medicine (2017) Vol. 376, Iss. 16, pp. 1517-1526
Open Access | Times Cited: 323
Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials
Xinlin Zhang, Qingqing Zhu, Li Zhu, et al.
BMC Medicine (2015) Vol. 13, Iss. 1
Open Access | Times Cited: 241
Lipid management in patients with chronic kidney disease
Charles J. Ferro, Patrick B. Mark, Mehmet Kanbay, et al.
Nature Reviews Nephrology (2018) Vol. 14, Iss. 12, pp. 727-749
Open Access | Times Cited: 205
Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized Controlled Trials
Aris Karatasakis, Barbara A. Danek, Judit Karácsonyi, et al.
Journal of the American Heart Association (2017) Vol. 6, Iss. 12
Open Access | Times Cited: 196
Citrus Flavonoids as Regulators of Lipoprotein Metabolism and Atherosclerosis
Erin E. Mulvihill, Amy C. Burke, Murray W. Huff
Annual Review of Nutrition (2016) Vol. 36, Iss. 1, pp. 275-299
Open Access | Times Cited: 195
Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?
Robert P. Giugliano, Marc S. Sabatine
Journal of the American College of Cardiology (2015) Vol. 65, Iss. 24, pp. 2638-2651
Open Access | Times Cited: 187
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
Amand F. Schmidt, Lucy S Pearce, John T. Wilkins, et al.
Cochrane library (2017)
Open Access | Times Cited: 179
Antibodies to watch in 2016
Janice M. Reichert
mAbs (2015) Vol. 8, Iss. 2, pp. 197-204
Open Access | Times Cited: 172
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition
Nathalie Bergeron, Binh An P. Phan, Yunchen Ding, et al.
Circulation (2015) Vol. 132, Iss. 17, pp. 1648-1666
Open Access | Times Cited: 169
Antibodies to watch in 2015
Janice M. Reichert
mAbs (2014) Vol. 7, Iss. 1, pp. 1-8
Open Access | Times Cited: 158
Long-term Low-Density Lipoprotein Cholesterol–Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia
Michael J. Koren, Marc S. Sabatine, Robert P. Giugliano, et al.
JAMA Cardiology (2017) Vol. 2, Iss. 6, pp. 598-598
Open Access | Times Cited: 157
The impact of genome‐wide association studies on the pathophysiology and therapy of cardiovascular disease
Thorsten Kessler, Baiba Vilne, Heribert Schunkert
EMBO Molecular Medicine (2016) Vol. 8, Iss. 7, pp. 688-701
Open Access | Times Cited: 154
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Massimo Piepoli
International Journal of Behavioral Medicine (2017) Vol. 24, Iss. 3, pp. 321-419
Closed Access | Times Cited: 141
A cholesterol-lowering VLP vaccine that targets PCSK9
Erin Crossey, Marcelo Amar, Maureen Sampson, et al.
Vaccine (2015) Vol. 33, Iss. 43, pp. 5747-5755
Open Access | Times Cited: 139
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Massimo Piepoli, Arno W. Hoes, Stefan Agewall, et al.
Kardiologia Polska (2016) Vol. 74, Iss. 9, pp. 821-936
Open Access | Times Cited: 122
National Lipid Association Annual Summary of Clinical Lipidology 2016
Harold Bays, Peter H. Jones, Carl E. Orringer, et al.
Journal of clinical lipidology (2016) Vol. 10, Iss. 1, pp. S1-S43
Open Access | Times Cited: 122
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
Amand F. Schmidt, John-Paul Carter, Lucy S Pearce, et al.
Cochrane library (2020) Vol. 2020, Iss. 12
Open Access | Times Cited: 112
PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo
Elise F. Villard, Aurélie Thedrez, Jörg Blankenstein, et al.
JACC Basic to Translational Science (2016) Vol. 1, Iss. 6, pp. 419-427
Open Access | Times Cited: 108
The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9
Nabil G. Seidah, Marianne Abifadel, Stefan Prost, et al.
Pharmacological Reviews (2016) Vol. 69, Iss. 1, pp. 33-52
Open Access | Times Cited: 106
Management of patients with familial hypercholesterolaemia
Željko Reiner
Nature Reviews Cardiology (2015) Vol. 12, Iss. 10, pp. 565-575
Closed Access | Times Cited: 106
Living the PCSK9 Adventure: from the Identification of a New Gene in Familial Hypercholesterolemia Towards a Potential New Class of Anticholesterol Drugs
Marianne Abifadel, Sandy Elbitar, Petra El Khoury, et al.
Current Atherosclerosis Reports (2014) Vol. 16, Iss. 9
Closed Access | Times Cited: 99
Page 1 - Next Page

Scroll to top